Paloma Partners Management Co Purchases 5,047 Shares of Repligen Co. (NASDAQ:RGEN)

Paloma Partners Management Co raised its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 267.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,932 shares of the biotechnology company's stock after buying an additional 5,047 shares during the period. Paloma Partners Management Co's holdings in Repligen were worth $1,032,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Champlain Investment Partners LLC grew its holdings in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock worth $84,387,000 after purchasing an additional 71,274 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

RGEN traded down $1.96 on Tuesday, hitting $148.50. The company's stock had a trading volume of 579,792 shares, compared to its average volume of 663,789. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The firm has a market cap of $8.32 billion, a P/E ratio of -401.34, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company's 50 day simple moving average is $141.29 and its 200-day simple moving average is $142.10.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 earnings per share. Analysts forecast that Repligen Co. will post 1.52 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on RGEN shares. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Benchmark reissued a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.